A Practice Note discussing federal merger enforcement actions against merging pharmaceutical companies. This Practice Note discusses market definition, theories of competitive harm, such as foreclosure, and remedies, such as divestitures and licenses, in recent federal consent decrees involving pharmaceutical mergers. This Practice Note also includes links to What's Market summaries in the Federal Merger Enforcement Action database.